First AD

Second AD

Focusing on the CLL13 and CLL14 studies, Bita Fakhri, MD, MPH, provides insights on the role of venetoclax-based first-line combination strategies.

Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL

Video content above is prompted by the following questions:

Discuss the role of venetoclax-based first-line (1L) combination treatment strategies.

How do you select patients for venetoclax + rituximab vs venetoclax + obinutuzumab vs venetoclax + ibrutinib?


Chronic Lymphocytic Leukemia

 Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy. 

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

My Treatment Approach: Improving Chronic Lymphocytic Leukemia Management and Treatment Outcomes

UCI Health Chao Family Comprehensive Cancer Center

Cancer Centers

Partner

Weill Cornell Medical College Sandra & Edward Meyer Cancer Center

Focusing on the CLL13 and CLL14 studies, Bita Fakhri, MD, MPH, provides insights on the role of venetoclax-based first-line combination strategies and factors that inform treatment selection.